Analyzing Enliven Therapeutics (NASDAQ:ELVN) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Risk & Volatility

Shionogi & Co., Ltd. Unsponsored ADR has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Shionogi & Co., Ltd. Unsponsored ADR and Enliven Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shionogi & Co., Ltd. Unsponsored ADR	0	0	0	0	0.00
Enliven Therapeutics	0	0	5	0	3.00

Enliven Therapeutics has a consensus target price of $41.20, suggesting a potential upside of 114.70%. Given Enliven Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Enliven Therapeutics is more favorable than Shionogi & Co., Ltd. Unsponsored ADR.

Valuation & Earnings

This table compares Shionogi & Co., Ltd. Unsponsored ADR and Enliven Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shionogi & Co., Ltd. Unsponsored ADR	$2.88 billion	5.28	$1.12 billion	N/A	N/A
Enliven Therapeutics	N/A	N/A	-$89.02 million	($2.00)	-9.60

Shionogi & Co., Ltd. Unsponsored ADR has higher revenue and earnings than Enliven Therapeutics.

Profitability

This table compares Shionogi & Co., Ltd. Unsponsored ADR and Enliven Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shionogi & Co., Ltd. Unsponsored ADR	N/A	N/A	N/A
Enliven Therapeutics	N/A	-29.15%	-27.88%

Institutional and Insider Ownership

1.9% of Shionogi & Co., Ltd. Unsponsored ADR shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 25.9% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Enliven Therapeutics beats Shionogi & Co., Ltd. Unsponsored ADR on 6 of the 11 factors compared between the two stocks.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.